BioSpace News Archive

NeoChord, Inc., a privately-held medical technology company leading the advancement of beating heart mitral valve repair in patients suffering from mitral valve regurgitation, today announced successful completion of the first-in-human procedure with the NeoChord NeXuS Transcatheter Mitral Chordal Repair technology (TMVr).

Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced new clinical and preclinical research will be presented at the 2021 AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics, taking place October 7 - 10, 2021.

Biophytis SA announces the issuance of 240 Bonds Redeemable in Cash and New and Existing Shares for a total amount of €6 million under its existing convertible bond agreement with Atlas, a specialized investment fund based in New York for €24 million.

Conformis, Inc. (NASDAQ: CFMS) announced today that it will release its financial results for the third quarter ended September 30, 2021 after the market closes on November 3, 2021 at approximately 4:00 p.m. Eastern Time.

RAIN Group, a global sales training company delivering award-winning results through in-person and virtual sales training, coaching, and reinforcement, announced today the release of its guide 36 Powerful Sales Questions for Life Sciences.

BioIVT, a leading provider of research models and services for drug and diagnostic development, today announced that it has added advanced tissue, biofluid and cell search and e-commerce capabilities to its website at www.bioivt.com.

Telix Pharmaceuticals Limited (ASX: TLX, ‘Telix’, the ‘Company’) today announces that a first patient has been dosed in a Phase II study of TLX250-CDx (89Zr-DFO-girentuximab) in patients with triple-negative breast cancer (TNBC) at the Institut de Cancérologie de l’Ouest (ICO) in St Herblain, France.

Exicure, Inc.® (NASDAQ: XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) technology, today announced a presentation at the Chardan Virtual 5th Annual Genetic Medicines Conference on Tuesday, October 5, 2021.

Humanigen, Inc., a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm,’ announced that management will present and participate at multiple virtual investor conferences in October 2021.